Methods and apparatus for dissolving intracranial blood clots

• US 20110160621A1
• Filed: 01/04/2011
• Published: 06/30/2011
• Est. Priority Date: 06/24/2005
• Status: Abandoned Application

• Current Assignee: Penumbra, Inc.
• Original Assignee: Penumbra, Inc.
• Inventors: Nita, Henry
• Application Number:
  US12/930,364
• Publication Number:
  US 20110160621A1
• Time in Patent Office: Days
• US Class Current: 601/2
• CPC Class Codes: A61B 2017/22008 used or promoted
• CPC Class Codes: A61B 34/20 Surgical navigation systems; Devices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
• CPC Class Codes: A61B 6/12 Arrangements for detecting or locating foreign bodies
• CPC Class Codes: A61B 8/0808 for diagnosis of the brain
• CPC Class Codes: A61B 90/11 with guides for needles or instruments, e.g. arcuate slides or ball joints
• CPC Class Codes: A61N 7/022 intracavitary

Abstract

A method for dissolving blood clots in a patient'"'"'s intracranial space using ultrasound energy involves forming at least one hole in the patient'"'"'s skull, advancing at least one ultrasound delivery device through the hole, and transmitting ultrasound energy from the ultrasound delivery device into blood clots. According to various embodiments, ultrasound delivery devices may be advanced into the epidural space, one or both ventricles and/or an intracerebral space of the patient'"'"'s brain. Also, one or more pharmacologic agent maybe delivered to the patient intracranial space to further facilitate clot dissolving therapy. Intracranial ultrasound delivery may be used to dissolve intracranial blood clots in relation to ischemic stroke, hemorrhagic stroke, head trauma, atherosclerosis, perfusion disorders and other acute or chronic neurological conditions.

Claims

1. A method for dissolving blood clots in a patient'"'"'s intracranial space using ultrasound energy, the method comprising:

forming at least one hole in the patient'"'"'s skull to access blood clots;

advancing an ultrasound device having a distal portion through the hole;

moving the distal portion to a desired location within the intracranial space;

transmitting ultrasound energy at frequencies between 10 KHz and 20 MHz from the ultrasound device.

2. The method of claim 1, wherein the blood clot resides in the intracerebral location of the intracranial space.

3. The method of claim 1, wherein the blood clot resides underneath the dura mater located within the intracranial space.

4. The method of claim 1, wherein the blood clot resides in the epidural location of the intracranial space.

5. The method of claim 1, wherein advancing the ultrasound device comprises advancing the device into the patient'"'"'s epidural space.

6. The method of claim 1, wherein advancing the ultrasound device comprises advancing the device into at least one ventricle of the patient'"'"'s brain.

7. The method of claim 1, wherein advancing the ultrasound device comprises advancing the device into an intracerebral space of the patient'"'"'s brain.

8. The method of claim 1, wherein advancing the ultrasound device comprises advancing the device underneath the dura mater of the patient'"'"'s brain.

9. The method of claim 1, wherein an introducer device is positioned in the burr hole prior to advancing the ultrasound device.

10. The method of claim 9, wherein the introducer device is positioned adjacent to the blood clot.

11. The method of claim 9, wherein the introducer is positioned inside the blood clot.

12. The method of claim 11, further comprising placing the ultrasound device through the introducer into the blood clot.

13. The method of claim 1, wherein advancing the ultrasound device comprises advancing a device selected from the group consisting of an ultrasound transducer and a transducer-tipped ultrasound catheter.

14. The method of claim 1, further comprising delivering at least one pharmacologic agent to blood clots.

15. The method of claim 14, wherein the agent is selected from a group consisting of blood clot reducing agents such as tissue plasminogen activator, tPA, BB-10153, rTPA, Urokinease, Streptokinase, Alteplase and Desmoteplase, antiplatelet agents such as aspirin, Clopidorgel and Ticclopidine, and GIIb/IIIa inhibitors, such as Abciximab, Tirofiban and Eptifibatide.

16. The method of claim 1, further comprising delivering microbubbles or nanobubbles to blood clots.

17. The method of claim 1, further comprising monitoring the positioning of the ultrasound device using a neuronavigation system.

18. The method of claim 12, further comprising monitoring the positioning of an introducer device inside blood clots using a neuronavigation system.

19. The method of claim 1, further including removing blood clots to the outside of the head.

20. The method of claim 19, wherein the removal of blood clots to the outside of the head is accomplished by one of the following techniques selected from the group consisting of:

aspiration, drainage by gravity or combination of both.

21. A method for dissolving blood clots in patient'"'"'s intracranial space, comprising the step of advancing an ultrasound device to a blood clot through the hole in the head and operating at frequencies between 10 KHz and 20 MHz.

22. The method of claim 21, wherein the distal end of the ultrasound device is positioned at one of the following locations:

adjacent to blood clots, inside blood clots or a combination of both.

23. The method of claim 21, further comprising cooling brain tissue during the blood clot dissolving procedure.

24. The method of claim 23, wherein brain cooling includes one of the following:

neck and head cooling, systemic body cooling, or a combination of both.